dr reddy's corporate social responsibility

6
Dr. Reddy’s Labs Nikhil Jhanb (C023) Ann Mary Mathew (C027) Gaurav Mehrotra (C028) Shraman Saha Roy (C041) Viresh Sharma (C049) Stuttee Arora (C061)

Upload: nikhil-jhanb

Post on 09-Feb-2018

241 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Dr Reddy's Corporate Social Responsibility

7/22/2019 Dr Reddy's Corporate Social Responsibility

http://slidepdf.com/reader/full/dr-reddys-corporate-social-responsibility 1/7

Dr. Reddy’s Labs 

Nikhil Jhanb (C023)

Ann Mary Mathew (C027)

Gaurav Mehrotra (C028)

Shraman Saha Roy (C041)

Viresh Sharma (C049)

Stuttee Arora (C061)

Page 2: Dr Reddy's Corporate Social Responsibility

7/22/2019 Dr Reddy's Corporate Social Responsibility

http://slidepdf.com/reader/full/dr-reddys-corporate-social-responsibility 2/7

Introduction

Healthcare Statistics▪ Healthcare policies in India

▪ Health crisis in developing Countries

▪ Beyond Philanthropy: The pharmaceutical Industry and CSR

Nikhil Ann Gaurav Shramana Viresh

Page 3: Dr Reddy's Corporate Social Responsibility

7/22/2019 Dr Reddy's Corporate Social Responsibility

http://slidepdf.com/reader/full/dr-reddys-corporate-social-responsibility 3/7

Healthcare statistics

Parameter Population(in billion)

LifeExpectancy

at birth

LifeExpectancy

at 60

InfantMortality

Rate

Under 5mortality

rate

Totalexpend

on hea

of G

India 1.241 65.48 16 47 61 3.9

USA .311 78.64 23 6 8 17.9

China 1.344 73.49 25 13 15 5.2

Page 4: Dr Reddy's Corporate Social Responsibility

7/22/2019 Dr Reddy's Corporate Social Responsibility

http://slidepdf.com/reader/full/dr-reddys-corporate-social-responsibility 4/7

Healthcare in India

▪ Universal Health Coverage

▪ 12th Five Year Plan

▪ High Level Expert Group-

▪ Generic Drugs

▪ 3% of GDP investment in Healthcare (world median 5%)*

▪ Rashtriya Swasthya Bima Yojana

▪ National Rural Health Mission

▪ Janani Suraksha Yojna

▪ Janani Shishu Suraksha Karyakram

▪ MDG’s 

▪ Reduce Child Mortality

▪ Improve Maternal Health

▪ Combat HIV/AIDS, malaria and other diseases

▪ 70% of total health spending is out of pocket, and around 70%of that is on drugs

▪ Private medical sector - 70% of households in urban areas

▪ Private medical sector - 63% of households in rural areas

*Public Spending -1.7%

USA- 7%+

Page 5: Dr Reddy's Corporate Social Responsibility

7/22/2019 Dr Reddy's Corporate Social Responsibility

http://slidepdf.com/reader/full/dr-reddys-corporate-social-responsibility 5/7

Health crisis in Developing Countries

▪ 14 million deaths due to infectious diseases, majorly poor

people in developing countries

▪ Just 12 diseases account for 20% of the global disease anddisability burden

▪ Infectious diseases overall are responsible for 63 percent ofdeaths of children aged under five years

▪ Poor countries carry 99 per cent of the global burden ofthese twelve diseases

▪ The pharmaceutical industry has grown in value by 700 per

cent since 1980.

▪ Less than 10 per cent of world pharmaceutical sales are todeveloping countries

▪ Spending on R&D is also skewed away from the developingworld with only 10 per cent of the global pharmaceuticalresearch and development expenditure going towardsdiseases that account for 90 per cent of the world’s diseaseburden.

48.

23.70%

16.20%

6.00%

5.90%

of pharmaceutical sales

Page 6: Dr Reddy's Corporate Social Responsibility

7/22/2019 Dr Reddy's Corporate Social Responsibility

http://slidepdf.com/reader/full/dr-reddys-corporate-social-responsibility 6/7

Beyond Philanthropy: The pharmaceutical Industr

CSR

Pricing

•Substantially lower prices in Developingnations

•Publish list of prices

•Price reduction should cover a range ofproducts relevant to the health priorities indeveloping nations

Patents

•Refrain from enforcing patents whichexacerbates health problems

•Support generic drugs where patents arenot in force

•Refrain from lobbying for stronger patentprotection

•Disclose details regarding lobbying

Joint Public Priv

•Resolving health pbusiness plan

•Must include vulne

•Transparency

•Integrate and strensystem

Research & Development•Publishing expenditure on R&D on

infectious diseases

•Forego patent in developing countries ondrugs developed for infectious diseases

Appropriate Use of Medicines•Support and comply with WHO guidelines

for Good Clinical Practice for trials

•Publish full results of clinical trials

•Support and comply with WHO Ethicalcriteria for Medicinal Drug Promotion

•Active drug safety monitoring

•Disclose full list of adverse drug reactions

Page 7: Dr Reddy's Corporate Social Responsibility

7/22/2019 Dr Reddy's Corporate Social Responsibility

http://slidepdf.com/reader/full/dr-reddys-corporate-social-responsibility 7/7